Loading...
XNAS
IVF
Market cap1mUSD
Dec 05, Last price  
1.54USD
1D
-6.10%
1Q
88.03%
IPO
-93.92%
Name

INVO Bioscience Inc

Chart & Performance

D1W1MN
XNAS:IVF chart
P/E
P/S
0.16
EPS
Div Yield, %
Shrs. gr., 5y
4.98%
Rev. gr., 5y
34.57%
Revenues
7m
+116.25%
0037,99563,20467,64871,50356,37727,06316,58811,68950,901282,145494,3751,480,2131,037,2864,160,116822,1963,020,5756,532,000
Net income
-9m
L+13.21%
-7,386-43,386-1,873,405-4,661,469-153,430-797,471-666,454-760,679-1,732,472-4,959,247-2,124,252-702,163-3,076,091-2,167,544-8,347,316-6,654,940-10,892,511-8,034,612-9,095,838
CFO
-3m
L-37.45%
-1,011-12,941-1,066,629-926,664-315,992-117,779-43,209-59,916-19,401-151,622-323,900-181,270-652,9711,370,513-4,775,148-6,029,914-6,603,319-4,755,054-2,974,400

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
IPO date
Nov 11, 2008
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT